Summit Therapeutics logo

Summit TherapeuticsNASDAQ: SMMT

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

05 March 2015

Next earnings report:

20 February 2025

Last dividends:

N/A

Next dividends:

N/A
$14.00 B
-42%vs. 3y high
95%vs. sector
-vs. 3y high
-vs. sector
-81%vs. 3y high
98%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Thu, 21 Nov 2024 00:59:46 GMT
$18.99-$1.09(-5.43%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

SMMT Latest News

Why Summit Therapeutics Stock Was a Winner Today
fool.com04 November 2024 Sentiment: POSITIVE

A cancer drug has vast potential for the company, says a pundit newly following it.

Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
benzinga.com04 November 2024 Sentiment: POSITIVE

JMP Securities initiated coverage on Summit Therapeutics Inc. SMMT, noting the company's initial focus on infectious disease. Later, in 2022, the company pivoted to oncology and in-licensed ivonescimab (PD-1 X VEGF bispecific) from Akeso for $500 million upfront and $5 billion in potential milestones.

Summit Therapeutics Posts Wider-Than-Expected Loss in Q3, Nil Sales
zacks.com31 October 2024 Sentiment: NEGATIVE

SMMT's third-quarter earnings miss estimates. Management also provides updates on the company's pipeline.

Summit Therapeutics Inc. (SMMT) Q3 2024 Earnings Call Transcript
seekingalpha.com30 October 2024 Sentiment: NEUTRAL

Summit Therapeutics Inc. (NASDAQ:SMMT ) Q3 2024 Earnings Conference Call October 30, 2024 9:00 AM ET Company Participants Dave Gancarz - Chief Business and Strategy Officer Bob Duggan - Chairman and CEO Maky Zanganeh - CEO and President Manmeet Soni - COO and CFO Allen Yang - Chief Medical Officer Conference Call Participants Mitchell Kapoor - H. C. Wainwright Brad Canino - Stifel Yigal Nochomovitz - Citi Operator Good morning.

Is Summit Therapeutics a Millionaire Maker?
fool.com27 October 2024 Sentiment: POSITIVE

The potential upside of this stock is undeniably meaty.

Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?
fool.com24 October 2024 Sentiment: POSITIVE

This drugmaker's lead candidate could become a top-selling cancer therapy.

Billionaire Israel Englander Just Quietly Took a Stake in This Potentially Lucrative Pharmaceutical Stock. Should You?
fool.com22 October 2024 Sentiment: POSITIVE

Millennium Management just initiated a position in a small biotech company developing a new cancer drug.

Up 700% This Year, Is It Too Late to Invest in This Stock?
https://www.fool.com/investing/2024/10/15/up-700-this-year-is-it-too-late-to-invest-in-this/15 October 2024 Sentiment: POSITIVE

The shares have experienced a pullback in the past couple of weeks.

Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics
fool.com13 October 2024 Sentiment: POSITIVE

It's hard to go wrong with either company, but one is more appealing.

3 Things You Need to Know If You Buy Summit Therapeutics Stock Today
fool.com12 October 2024 Sentiment: POSITIVE

It's easier to invest confidently when you know both the pros and the cons in full.

  • 1(current)
  • 2
  • 3

What type of business is Summit Therapeutics?

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

What sector is Summit Therapeutics in?

Summit Therapeutics is in the Healthcare sector

What industry is Summit Therapeutics in?

Summit Therapeutics is in the Biotechnology industry

What country is Summit Therapeutics from?

Summit Therapeutics is headquartered in United States

When did Summit Therapeutics go public?

Summit Therapeutics initial public offering (IPO) was on 05 March 2015

What is Summit Therapeutics website?

https://www.summittxinc.com

Is Summit Therapeutics in the S&P 500?

No, Summit Therapeutics is not included in the S&P 500 index

Is Summit Therapeutics in the NASDAQ 100?

No, Summit Therapeutics is not included in the NASDAQ 100 index

Is Summit Therapeutics in the Dow Jones?

No, Summit Therapeutics is not included in the Dow Jones index

When was Summit Therapeutics the previous earnings report?

No data

When does Summit Therapeutics earnings report?

The next expected earnings date for Summit Therapeutics is 20 February 2025